Edition:
United Kingdom

Vical Inc (VICL.OQ)

VICL.OQ on NASDAQ Stock Exchange Capital Market

1.48USD
23 Feb 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.48
Open
$1.49
Day's High
$1.52
Day's Low
$1.46
Volume
50,530
Avg. Vol
44,665
52-wk High
$3.69
52-wk Low
$1.32

Chart for

About

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including... (more)

Overall

Beta: 1.99
Market Cap(Mil.): $30.56
Shares Outstanding(Mil.): 11.40
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Vical Announces Restructuring To Focus Resources On Hsv-2 And Antifungal Clinical Programs

* VICAL ANNOUNCES RESTRUCTURING TO FOCUS RESOURCES ON HSV-2 AND ANTIFUNGAL CLINICAL PROGRAMS

30 Jan 2018

BUZZ-Vical: Falls as herpes vaccine fails late-stage trial

** Drugmaker's shares fall 27.81 pct to $1.35 - top pct loser among Nasdaq-listed stocks premarket

22 Jan 2018

BRIEF-‍Stonepine Capital Management reports 6.6 pct passive stake in Vical

* ‍Stonepine Capital Management Llc reports 6.6 percent passive stake in Vical Inc as on November 8, 2017 - SEC filing​ Source text: (http://bit.ly/2z2Y7Nh) Further company coverage:

15 Nov 2017

BRIEF-Vical Incorporated announces pricing of $25 mln underwritten public offering of common stock

* Vical Incorporated announces pricing of $25 million underwritten public offering of common stock

08 Nov 2017

BRIEF-VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON TREATMENT FOR CHRONIC HEPATITIS B INFECTION

* VICAL ANNOUNCES JOINT DEVELOPMENT PROGRAM WITH ANGES ON A TREATMENT FOR CHRONIC HEPATITIS B INFECTION

24 Oct 2017

BRIEF-Vical reports Q3 loss per share $0.27

* Vical reports third quarter 2017 financial and operational results

23 Oct 2017

BRIEF-Vical Inc files for common stock offering of up to $23.0 mln

* Vical Inc files for common stock offering of up to $23.0 million - SEC filing‍​ Source: (http://bit.ly/2gnoSUA) Further company coverage:

16 Oct 2017

BRIEF-Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

* Vical announces completion of the Phase 3 ASP0113 CMV vaccine trial

10 Oct 2017

BRIEF-Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA

* Vical announces that its antifungal VL-2397 is eligible for limited use indication approval by FDA based on a single phase 2 efficacy trial

02 Oct 2017

Competitors

  Price Chg
Sanofi SA (SASY.PA) €65.05 --
Novartis AG (NOVN.S) CHF79.38 -0.60
GlaxoSmithKline plc (GSK.L) 1,296.00 -7.00
AstraZeneca plc (AZN.L) 4,752.00 -20.00
Merck & Co., Inc. (MRK.N) $54.87 +0.30
Pfizer Inc. (PFE.N) $36.26 +0.52
Roche Holding Ltd. (ROG.S) CHF222.05 -1.25
Roche Holding Ltd. (RO.S) CHF225.80 -0.60
Genocea Biosciences Inc (GNCA.OQ) $1.02 0.00
Agenus Inc (AGEN.OQ) $5.06 +0.21

Earnings vs. Estimates